Currently, standard first-line chemotherapy with or without immunotherapy for patients with non-small-cell lung cancer (NSCLC) with HER2 mutations has limited efficacy.
Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners
Latest from Memorial Sloan Kettering Cancer Center
The CEPHEUS trial also highlights the importance of minimal residual disease (MRD) as a study end point.
IMROZ study data show Isa-VRd may be a new standard of care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Scrutiny of GLP-1 Compounding Is Just Getting Started, Expert Says
2
Menin Inhibitors in AML: Frequently Asked Questions
3
From Misnomer to Meaning: A Patient-Centered Shift from PCOS to PMOS
4
FDA Approves Veligrotug-vvze as First Agent With Data in Both Active and Chronic Thyroid Eye Disease
5